Copyright
©The Author(s) 2016.
World J Ophthalmol. Aug 12, 2016; 6(3): 20-27
Published online Aug 12, 2016. doi: 10.5318/wjo.v6.i3.20
Published online Aug 12, 2016. doi: 10.5318/wjo.v6.i3.20
Figure 1 Structures of compounds used in the current studies.
BK: Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg; Met-Lys-BK: Met-Lys-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg; RMP-7: H-Arg-Pro-Hyp-Gly-Thi-Ser-Pro-4-Me-Tyrψ(CH2NH)-Arg-OH; Des-Arg9-BK: Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe. A: FR-190997. HOE-140: H-D-Arg-Arg-Pro-Hyp-Gly-Thi-Ser-D-Tic-Oic-Arg-OH (peptide B2-receptor antagonist); D: D configuration of amino acid; D-BT: (3S)[amino]-5-(carbonylmethyl)-2,3-dihydro-1,5-benzothiazepin-4(5H)-one; Hyp: Trans-4-Hydroxy-L-proline; Igl: α-(2-Indanyl)glycine; Oic: Octahydroindole-2-carboxylic acid; Thi: O-(2-thienyl)-alanine; Tic: L-1,2,3,4-Tetrahydroisoquinoline-3-carbonyl; TFA: Trifluoroacetic acid; B: WIN-64338 (non-peptide B2-receptor antagonist); C: Bromfenac sodium (cyclooxygenase inhibitor; prostaglandin synthase inhibitor).
- Citation: Sharif NA, Patil R, Li L, Husain S. Human ciliary muscle cell responses to kinins: Activation of ERK1/2 and pro-matrix metalloproteinases secretion. World J Ophthalmol 2016; 6(3): 20-27
- URL: https://www.wjgnet.com/2218-6239/full/v6/i3/20.htm
- DOI: https://dx.doi.org/10.5318/wjo.v6.i3.20